New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Where the cash went Twelve months to 30 September 2026

Free cash flow was −$13.7M: capital expenditures were more than operating cash flow. Cash rose by $173.9M. Lines the picture does not name came to +$184.0M. What is a cash flow statement?

Free cash flow
−$13.7M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$173.9M over the period
Where the cash went, in millions of dollars
Operating cash flow−13.7
Free cash flow−13.7
Shares issued, net+3.5
Other+184.0
Change in cash173.9

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more TTM periods

(13.56) (14.11) (13.44) (193.16)
Operating Cash Flow
(11.39) (12.25) (11.97) (13.66)
Investing cash flow
(0.85) (1.35) (1.16) (3.06)
Financing cash flow
16.58 12.39 6.40 190.67
Ending Cash
5.54 4.33 (1.20) 179.43

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 18 Nov 2026